{"filing":{"accession_number":"0001104659-26-079087","cik":"0001583648","ticker":"PVLA","company_name":"PALVELLA THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"tm2619348d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583648/000110465926079087/tm2619348d1_8k.htm"},"events":[{"id":14835,"run_id":13226,"accession_number":"0001104659-26-079087","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board appointed Matthew Pauls as a Class I director on June 29, 2026, increasing the Board size from seven to eight members. While the disclosure includes compensatory details (stock option grant of 6,000 shares), the principal disclosed action is the appointment of a new director with substantial industry experience in biopharmaceuticals. This is a governance event centered on a person taking a role, making exec_appointment the most salient classification.","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12394,"accession_number":"0001104659-26-079087","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Matthew Pauls as a Class I director on June 29, 2026, increasing the Board size from seven to eight members. While the disclosure includes compensatory details (stock option grant of 6,000 shares), the principal disclosed action is the appointment of a new director with substantial industry experience in biopharmaceuticals. This is a governance event centered on a person taking a role, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:37:36.930328+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12394,"accession_number":"0001104659-26-079087","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board appointed Matthew Pauls as a Class I director on June 29, 2026, increasing the Board size from seven to eight members. While the disclosure includes compensatory details (stock option grant of 6,000 shares), the principal disclosed action is the appointment of a new director with substantial industry experience in biopharmaceuticals. This is a governance event centered on a person taking a role, making exec_appointment the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-30T11:37:36.930328+00:00","company_name":"PALVELLA THERAPEUTICS, INC.","ticker":"PVLA","filing_date":"2026-06-30"}]}